Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

483 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
AXL signal mediates adaptive resistance to KRAS G12C inhibitors in KRAS G12C-mutant tumor cells.
Morimoto K, Yamada T, Hirai S, Katayama Y, Fukui S, Sawada R, Tachibana Y, Matsui Y, Nakamura R, Ishida M, Kawachi H, Kunimasa K, Sasaki T, Nishida M, Furuya N, Watanabe S, Shiotsu S, Nishioka N, Horinaka M, Sakai T, Uehara H, Yano S, Son BK, Tokuda S, Takayama K. Morimoto K, et al. Among authors: kawachi h. Cancer Lett. 2024 Apr 10;587:216692. doi: 10.1016/j.canlet.2024.216692. Epub 2024 Feb 9. Cancer Lett. 2024. PMID: 38342232 Free article.
Osimertinib is associated with reversible and dose-independent cancer therapy-related cardiac dysfunction.
Kunimasa K, Oka T, Hara S, Yamada N, Oizumi S, Miyashita Y, Kamada R, Funamoto T, Kawachi H, Kawamura T, Inoue T, Kuhara H, Tamiya M, Nishino K, Matsunaga T, Imamura F, Fujita M, Kumagai T. Kunimasa K, et al. Among authors: kawachi h. Lung Cancer. 2021 Mar;153:186-192. doi: 10.1016/j.lungcan.2020.10.021. Epub 2020 Nov 16. Lung Cancer. 2021. PMID: 33277055
Elective Nodal Irradiation for Non-small Cell Lung Cancer Complicated With Chronic Obstructive Pulmonary Disease Affects Immunotherapy Αfter Definitive Chemoradiotherapy.
Morimoto M, Nishino K, Wada K, Imamura F, Konishi K, Kuhara H, Tamiya M, Inoue T, Kunimasa K, Kimura M, Hirata T, Kanayama N, Toratani M, Kawachi H, Ohira K, Nakanishi E, Ohira S, Sagawa T, Miyazaki M, Matsunaga T, Kumagai T, Teshima T. Morimoto M, et al. Among authors: kawachi h. Anticancer Res. 2020 Dec;40(12):6957-6970. doi: 10.21873/anticanres.14720. Epub 2020 Dec 7. Anticancer Res. 2020. PMID: 33288590
Late recurrence of lung adenocarcinoma harboring EGFR exon 20 insertion (A763_Y764insFQEA) mutation successfully treated with osimertinib.
Kunimasa K, Nishino K, Kukita Y, Matsumoto S, Kawachi H, Kawamura T, Inoue T, Tamiya M, Honma K, Sugimoto N, Yamasaki T, Imamura F, Goto K, Kumagai T. Kunimasa K, et al. Among authors: kawachi h. Cancer Genet. 2021 Aug;256-257:57-61. doi: 10.1016/j.cancergen.2021.04.001. Epub 2021 Apr 10. Cancer Genet. 2021. PMID: 33901930
Adaptive resistance to lorlatinib via EGFR signaling in ALK-rearranged lung cancer.
Katayama Y, Yamada T, Tanimura K, Tokuda S, Morimoto K, Hirai S, Matsui Y, Nakamura R, Ishida M, Kawachi H, Yoneda K, Hosoya K, Tsuji T, Ozasa H, Yoshimura A, Iwasaku M, Kim YH, Horinaka M, Sakai T, Utsumi T, Shiotsu S, Takeda T, Katayama R, Takayama K. Katayama Y, et al. Among authors: kawachi h. NPJ Precis Oncol. 2023 Jan 26;7(1):12. doi: 10.1038/s41698-023-00350-7. NPJ Precis Oncol. 2023. PMID: 36702855 Free PMC article.
Rationale and design of phase II clinical trial of dual inhibition with ramucirumab and erlotinib in EGFR exon 19 deletion-positive treatment-naïve non-small cell lung cancer with high PD-L1 expression (SPIRAL-3D study).
Kawachi H, Yamada T, Yoshimura A, Morimoto K, Iwasaku M, Tokuda S, Kim YH, Shimose T, Takayama K. Kawachi H, et al. Ther Adv Med Oncol. 2023 Jun 12;15:17588359231177022. doi: 10.1177/17588359231177022. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 37333903 Free PMC article.
Concomitant Proton Pump Inhibitor Use With Pembrolizumab Monotherapy vs Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With Non-Small Cell Lung Cancer.
Kawachi H, Yamada T, Tamiya M, Negi Y, Goto Y, Nakao A, Shiotsu S, Tanimura K, Takeda T, Okada A, Harada T, Date K, Chihara Y, Hasegawa I, Tamiya N, Ishida M, Katayama Y, Morimoto K, Iwasaku M, Tokuda S, Kijima T, Takayama K. Kawachi H, et al. JAMA Netw Open. 2023 Jul 3;6(7):e2322915. doi: 10.1001/jamanetworkopen.2023.22915. JAMA Netw Open. 2023. PMID: 37432682 Free PMC article.
Effects of Combined Therapeutic Targeting of AXL and ATR on Pleural Mesothelioma Cells.
Hirai S, Yamada T, Katayama Y, Ishida M, Kawachi H, Matsui Y, Nakamura R, Morimoto K, Horinaka M, Sakai T, Sekido Y, Tokuda S, Takayama K. Hirai S, et al. Among authors: kawachi h. Mol Cancer Ther. 2024 Feb 1;23(2):212-222. doi: 10.1158/1535-7163.MCT-23-0138. Mol Cancer Ther. 2024. PMID: 37802502 Free PMC article.
483 results